Anthony J Olszanski, MD, RPh

« More

Publications

Peer Reviewed

Schiller JH, Larson T, Ou IS, et al. and Olszanski AJ, Efficacy and Safety of Axitinib in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase II Study. Journal Clinical Oncology, 27 (23); 3836-3841, 2009

M. Michael M, Vlahovic G, Khamly K, et al. and Olszanski AJ, Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel with or without axitinib, a VEGFR inhibitor. Clinical Cancer Research, (Submitted)

Lewis NL, Lewis LD, Eder JP, et al. and Olszanski AJ, Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific PDGFR tyrosine kinase inhibitor in patients with advanced cancers. Journal Clinical Oncology: Published Ahead of Print on September 8, 2009

Mita AC, Olszanski AJ, Walovitch RC, et al. Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. Clinical Cancer Research, 13 (11);3293-3301, 2007

Perez RP, Lewis LD, Beelen AP, Olszanski AJ, et al. Modulation of Cell-cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01. Clinical Cancer Research, 12 (23); 7070-7085, December 1, 2006

Olszanski AJ, Rigas JR. Docetaxel and gemcitabine: A non-platinum combination for non-small cell lung cancer. Clinical Lung Cancer, 1(S1):15-19 (2000)

Selected Abstracts

Martin L, et al. and Olszanski AJ, Phase I Study of Axitinib (AG-013736) in Combination with Chemotherapy in Patients with Advanced Solid Tumours. ESMO (2008) Abstract 472P; Poster

Rini BI, et al and Olszanski AJ, Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). ASCO (2008) Abstract 3543; Oral presentation

Michael M, et al. and Olszanski AJ, Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel (Doc) with or without AG-013736, a VEGF inhibitor. ASCO (2008) Abstract 3549; Poster

Lewis LD, Reddy NJ et al. and Olszanski AJ, Pharmacokinetics of an Oral Film-coated Tablet of CP-868,596,a PDGFR Inhibitor, in Patients with Advanced Cancers. ACR/NCI/EORTC (2008) Abstract 585; Poster

Schiller JH, et al. and Olszanski AJ, Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: a phase II trial. ASCO (2007) Abstract 7507; Oral presentation

Cohen RB, et al. and Olszanski AJ, Axitinib (AG-013736) in combination with paclitaxel/carboplatin in patients with advanced solid tumors. AACR/NCI/EORTC (2007) Abstract A157; Poster

Michael M, et al. and Olszanski AJ, Phase 1b study of oral CP-868,596, a highly specific PDGFR inhibitor, in combination with docetaxel. ACR/NCI/EORTC (2007) Abstract A148; Poster

Olszanski AJ, et al. Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel. ASCO (2004) Abstract 2048; Poster

Olszanski AJ, Lewis LD. Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion. ASCPT  (2004) Abstract; Poster PI-54

Olszanski AJ, Lowrey CH, Sporn MB, Suh N. The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) Inhibits Proliferation and Induces Apoptosis of Myeloma Cells in a Time and Dose-Dependent Fashion. Blood 100(11):816a (2002) Abstract 3224; Poster 644

Olszanski AJ, Lowrey CH, Sporn MB, Suh N. Human hematopoietic colony formation is highly sensitive to the novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid. Blood 98(11):119b (2001) Abstract 4128

Video

Introductory Video of Dr. Olszanski

Medical Oncology
Director, Clinical Pharmacology
Fox Chase Phase 1 Program

Meet the other members of the
Medical Oncology team.

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

New patients can request an appointment online or call 215-728-2570.

Appointments for Returning Patients

For general information, call:
1-888-FOX CHASE (1-888-369-2427).
An oncology certified nurse will assist you.

Clinical Expertise:

Phase 1 trials, gastrointestinal cancer and melanoma

Medical Education:

Biostatistics, Dartmouth Medical School Center for Evaluative Clinical Sciences, Hanover, NH 2003;
MD, University of Medicine and Dentistry of New Jersey, Newark, NJ, 1996
BS Pharmacy, University of Montana, Missoula, MT, 1990

Residency:

Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 1996-1999

Fellowships:

Clinical Pharmacology/Toxicology Fellowship, Oncology Phase I Program, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 2002-2004;
Hematology/Oncology Fellowship, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1999-2002

Certifications:

Medical Oncology
Clinical Pharmacology
Internal Medicine

Professional Societies:

American Society of Clinical Oncology;
American Board
of Clinical Pharmacology

Research Interests:

Early clinical drug discovery trials (phase 1 trials)